GOPCABE: similar results for in-pump or off-pump surgery in elderly patients

Background: There is much debate about a possible benefit of coronary artery bypass grafting (CABG) without cardiopulmonary bypass (CPB) compared with on-pump surgery. However, a randomized study could not confirm this benefit. The objective of these studies was to compare the MACCE, (death, MI, stroke, revascularization repeated and a new dialysis), of surgical revascularization with and without cardiopulmonary bypass (CBP) in patients over 75 years. 

Methods and results: A multicenter study randomized 2,539 patients over 75 years of age to CABG with CBP and without CPB. At thirty days after surgery, there was no significant difference between patients who underwent off-pump surgery and those who underwent on-pump surgery in terms of the composite outcome, (7.8% versus 8.2%, odds ratio, 0.95, confidence interval 95% CI, 0.71 to 1.28, P = 0.74), or when analyzed separately for the four components, (death, stroke, myocardial infarction or new dialysis). Revascularization was more frequent after CABG with CPB, (1.3% versus 0.4%, odds ratio 2.42, 95% CI, 1.03 to 5.72, P = 0.04). At twelve months, there were no significant differences between groups in the composite outcome, (13.1% versus 14.0%, odds ratio 0.93, 95% CI, 0.76 to 1.16, P = 0, 48), or any of the individual components. 

Conclusion: The GOBCABE randomized study showed no significant difference between revascularization with or without cardiopulmonary bypass (CBP) at thirty days and one year. 

Comments: This study showed no differences between CABG surgery with or without CBP in a high-risk population (elderly) and, therefore, more exposed to pump complications. Cognitive status and quality of life after surgery was not assessed which is a limitation. There are many confusing variables that can occur even with the surgeon’s experience with this technique.

anno_diegeler_acc2013_articulo
Anno Diegeler
2013-03-11

Original title: The German Off-Pump Coronary Artery Bypass Grafting in Elderly Patients (GOPCABE) Study. // Presentador:

More articles by this author

PARTNER cohort A at three years, the benefit continues

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The...

ASTRONAUT: Aliskiren failed to show benefits in patients with acute heart failure

Hospitalization for heart failure, (HF), represents a major health problem with high rates of death or early readmission after discharge. The aim of this...

RELAX Study: Phosphodieserase-5 inhibitors showed no benefit in heart failure with preserved ventricular function.

Phosphodieserase-5 enzyme is activated in heart failure and can limit the beneficial effects of nitric oxide, (NO), in the vasculature, kidney and myocardium. The...

STOP-HF: The use of B-type natriuretic peptide (BNP) for screening high-risk population decreases the prevalence of heart failure

B-type natriuretic peptide (BNP) can be a reliable marker for the diagnosis of heart failure (HF). This study aimed to assess whether the use...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....